Efficacy of convalescent plasma therapy in improving survival in non-immunized COVID-19 patients
Open Access
- 24 June 2025
- journal article
- Published by Springer Nature in Virology Journal
- Vol. 22 (1) , 206
Abstract
Purpose: Convalescent plasma (CP), obtained from individuals who have recovered from COVID-19, has been widely explored as a potential therapeutic option, particularly in the absence of vaccines and monoclonal antibody treatments. This study aimed to evaluate the effectiveness of CP therapy in improving survival among non-immunized COVID-19 patients hospitalized in Brazil. Methods: This retrospective unicentric cohort study was conducted at a private hospital in Campo Largo, Paraná, Brazil, from July 2020 to February 2021. A total of 245 hospitalized COVID-19 patients were included, confirmed by RT-qPCR or antigen testing. Patients were divided into two groups: those receiving CP alongside standard treatment (n=100) and those receiving standard treatment alone (n=145). Survival outcomes were assessed using Kaplan-Meier analysis and Cox regression, while inflammatory responses were evaluated through C-reactive protein (CRP) measurements. Results: Patients treated with CP had a significantly higher survival rate (91%) compared to the control group (82.8%) (P=0.0363). The survival benefit persisted throughout the follow-up period, with a 2.25-fold lower risk of death in the CP group after adjusting for age (P=0.0480). However, no significant differences in CRP levels were observed between groups at discharge, suggesting that CP's benefits may be mediated through immune modulation rather than direct anti-inflammatory effects. Conclusions: Our findings indicate that CP therapy significantly improves survival in non-immunized COVID-19 patients, reinforcing its potential role in settings with limited access to advanced treatments. Future studies should explore CP’s mechanisms of action and its integration into broader therapeutic strategies.Keywords
Funding Information
- Brazilian National Council for Scientific and Technological Development (442329/2019–9)
- Fiocruz, FIOTEC (VPPIS-004-FIO-18–40, VPPIS-004-FIO-18–40)
This publication has 41 references indexed in Scilit:
- Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor populationJournal of Clinical Investigation, 2020
- Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)BMJ, 2020
- Efficacy of convalescent plasma for the treatment of severe influenzaCritical Care, 2020
- Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19JAMA, 2020
- Convalescent plasma transfusion for the treatment of COVID‐19: Systematic reviewJournal of Medical Virology, 2020
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent PlasmaJAMA, 2020
- Effectiveness of convalescent plasma therapy in severe COVID-19 patientsProceedings of the National Academy of Sciences, 2020
- The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysisThe Journal of Infectious Diseases, 2014
- Hyperimmune IV Immunoglobulin TreatmentChest, 2013
- Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus InfectionClinical Infectious Diseases, 2011